Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8454812 | Lung Cancer | 2015 | 6 Pages |
Abstract
Approximately 10% of lung adenocarcinomas harbor aberrations that are targetable using the approved multitargeted TKI crizotinib. MET exon 14 skipping mutation predicts for response to MET TKIs in human lung adenocarcinomas but co-occurrence of PIK3CA mutation needs to be better evaluated as a modifier of response to TKI therapy. MET TKIs should not be omitted from MET exon 14 skipping mutated tumors until further preclinical and clinical data can confirm or refute mechanisms of primary or acquired resistance to crizotinib and other MET TKIs in these recalcitrant cancers.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Susan E. Jorge, Sol Schulman, Jason A. Freed, Paul A. VanderLaan, Deepa Rangachari, Susumu S. Kobayashi, Mark S. Huberman, Daniel B. Costa,